EMEA-001664-PIP02-15-M03

Key facts

Invented name
Aimovig
Active substance
erenumab
Therapeutic area
Neurology
Decision number
P/0107/2019
PIP number
EMEA-001664-PIP02-15-M03
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Prevention of migraine headaches
Route(s) of administration
  • Subcutaneous use
  • Intravenous use
Contact for public enquiries
Novartis Europharm Limited

Tel. +41 6132 41111
E-mail: paediatric.enquiries@novartis.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating